Atrial Fibrillation - Pipeline Insight, 2025

This “Atrial Fibrillation - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Atrial Fibrillation: Understanding

Atrial Fibrillation: Overview

Atrial fibrillation (AF) is the most common form of cardiac arrhythmia, characterized by irregular and often rapid electrical activity in the atria, leading to ineffective atrial contractions and disrupted blood flow. This condition significantly increases the risk of thrombus formation and subsequent stroke, making it a major cardiac cause of stroke. AF can present in various forms - paroxysmal or persistent - and its symptoms range from none to severe, including palpitations, chest pain, dizziness, and fatigue. Risk factors include aging, hypertension, heart and lung disease, and lifestyle factors such as alcohol use. Despite its chronic nature, AF can be managed through medications, anticoagulation, cardioversion, ablation, and other cardiac interventions aimed at symptom control and stroke prevention.

Common symptoms of atrial fibrillation include palpitations, shortness of breath, fatigue, dizziness, and chest pain. Some individuals may also experience weakness, confusion, lightheadedness, excessive sweating, and a reduced ability to tolerate physical activity. In some cases, nausea or vomiting may also occur, and symptoms can vary widely in severity and frequency among individuals. These symptoms can be persistent or come and go, and they may worsen with exertion or stress. For some, atrial fibrillation may be asymptomatic and only discovered during a routine exam. However, when symptoms are present, they can significantly impact quality of life and daily functioning. Prompt medical attention is important, especially when symptoms are severe or accompanied by signs of stroke.

Atrial fibrillation (AF) is primarily driven by structural and electrical cardiac remodeling, particularly in the atria. Conditions like hypertension, valvular, structural, and ischemic heart disease often contribute to its development, with some genetic factors - such as mutations on chromosome 10 - playing a role. Ectopic electrical foci, usually near the pulmonary veins, cause the atria to fibrillate irregularly, leading to poor blood flow and increased thrombus risk. Common triggers include ischemia, inflammation, alcohol use, and advanced age. Clinical evaluation involves a thorough history and physical exam to identify symptoms, risk factors, and underlying causes, helping guide effective diagnosis and management.

The acute management of atrial fibrillation (AF) hinges on the patient’s hemodynamic stability and risk of stroke. Unstable patients require immediate cardioversion, often alongside anticoagulation, with or without prior transesophageal echocardiography (TEE). Rate control is typically achieved with beta-blockers or calcium channel blockers; digoxin and amiodarone are alternatives but not first-line. For stable, preexisting AF, stroke risk is assessed using the CHA2DS2-VASc score to guide anticoagulation decisions, while bleeding risk is evaluated with the HAS-BLED score. Long-term management may include medications for rate or rhythm control, catheter ablation, or pacemaker insertion. Current guidelines favor non-vitamin K oral anticoagulants over warfarin and recommend lifestyle modifications, such as weight loss, in appropriate patients.
"Atrial Fibrillation - Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atrial Fibrillation pipeline landscape is provided which includes the disease overview and Atrial Fibrillation treatment guidelines. The assessment part of the report embraces, in depth Atrial Fibrillation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atrial Fibrillation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Atrial Fibrillation R&D. The therapies under development are focused on novel approaches to treat/improve Atrial Fibrillation.

Atrial Fibrillation Emerging Drugs Chapters

This segment of the Atrial Fibrillation report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atrial Fibrillation Emerging Drugs

Abelacimab: Anthos Therapeutics, Inc.

Abelacimab is a novel, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease. As a fully human monoclonal antibody, abelacimab is not metabolized via the cytochrome P450 system or as a substrate for P-glycoprotein, meaning the risk for drug-drug interactions is very unlikely. There is also no need to adjust the dose based on age or renal/hepatic status and it can be safely co-administered with antiplatelet agents. Abelacimab is currently being evaluated in several ongoing Phase III clinical trials for patients at risk of dangerous arterial and venous clots, including those with atrial fibrillation and cancer associated thrombosis. In patients with atrial fibrillation, abelacimab is planned to be dosed subcutaneously once-monthly with an autoinjector to maintain near-complete inhibition in a chronic setting. It is also planned to be administered via an initial intravenous (IV) infusion for acute indications requiring immediate onset of action and then followed by subsequent monthly subcutaneous administration. Currently, the drug is in Phase III stage of its development for the treatment of Atrial Fibrillation.

Etripamil: Milestone Pharmaceuticals Inc.

Etripamil is a fast-acting, intranasal calcium channel blocker developed for the acute management of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). Designed for self-administration, it is delivered via a nasal spray, allowing for quick absorption through the nasal mucosa, with onset of action typically within 10 minutes. Etripamil acts rapidly to control heart rate by blocking calcium influx into cardiac cells, helping to slow conduction through the atrioventricular (AV) node. Its short duration of action may reduce the risk of long-term side effects commonly associated with continuous use of traditional antiarrhythmic medications, making it a convenient and potentially safer option for managing sudden AFib episodes. Currently, the drug is in Phase II stage of its development for the treatment of Atrial Fibrillation.

THRV-1268: Thryv Therapeutics, Inc.

THRV-1268 is a novel and potent inhibitor of the Serum Glucocorticoid Kinase 1 (SGK1). SGK1 is a PI3-kinase-dependent kinase with its expression and activation regulated by several metabolic signaling pathways that are crucial in cardiometabolic diseases. Thryv Therapeutic’s first SGK1 inhibitor, LQT-1213, repeatedly demonstrated reductions in QTc interval in pre-clinical studies and in patients with the genetic and acquired Long QT Syndrome. SGK1 has been implicated in various pathological conditions, including QTc prolongation, arrhythmias, fibrosis, and heart failure. SGK1 dysfunction is also linked to cardiometabolic stressors such as obesity and hypertension, which are common comorbidities in heart failure. Genetic and pharmacological inhibition of SGK1 has been demonstrated to have a protective effect in a mouse model of obesity-related atrial fibrillation. In several preclinical models of heart failure, THRV-1268 mitigated the development of heart failure and fibrosis, and reduced heart failure biomarkers associated with adverse changes in hemodynamic and functional cardiovascular outputs. These findings demonstrate the potential of SGK1 inhibition in addressing the pathogenesis of heart failure and related cardiometabolic conditions, including atrial fibrillation. Currently, the drug is in Phase I stage of its development for the treatment of Atrial Fibrillation.

Atrial Fibrillation: Therapeutic Assessment

This segment of the report provides insights about the different Atrial Fibrillation drugs segregated based on following parameters that define the scope of the report.

Major Players in Atrial Fibrillation

• There are approx. 10+ key companies which are developing the therapies for Atrial Fibrillation. The companies which have their Atrial Fibrillation drug candidates in the most advanced stage, i.e. Phase III include, Anthos Therapeutics, Inc.

Phases
The report covers around 12+ products under different phases of clinical development, like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of:
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atrial Fibrillation: Pipeline Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Atrial Fibrillation therapeutic drugs key players involved in developing key drugs.

Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrial Fibrillation drugs.

Atrial Fibrillation Report Insights

• Atrial Fibrillation Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Atrial Fibrillation Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Atrial Fibrillation drugs?
• How many Atrial Fibrillation drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atrial Fibrillation?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atrial Fibrillation therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Atrial Fibrillation and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Thryv Therapeutics, Inc.
• Janssen Research & Development, LLC
• HUYABIO International, LLC.
• Milestone Pharmaceuticals Inc.
• Anthos Therapeutics, Inc.
• Bayer

Key Products

• THRV-1268
• Milvexian
• HBI-3000
• Etripamil
• Abelacimab
• Research program

This product will be delivered within 2 business days.